Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Xenetic Biosciences Inc XBIO

Healthcare Biotechnology
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company’s proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma,... see more

Recent & Breaking News (NDAQ:XBIO)

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

ACCESS Newswire November 19, 2025

Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results

ACCESS Newswire November 13, 2025

Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock

ACCESS Newswire October 10, 2025

Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results

ACCESS Newswire August 13, 2025

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

ACCESS Newswire July 30, 2025

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

ACCESS Newswire July 23, 2025

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

ACCESS Newswire July 8, 2025

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

ACCESS Newswire May 14, 2025

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

ACCESS Newswire April 9, 2025

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma

ACCESS Newswire March 26, 2025

Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results

ACCESS Newswire March 19, 2025

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses

ACCESS Newswire March 13, 2025

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting

ACCESS Newswire February 27, 2025

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

ACCESS Newswire December 17, 2024

Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

ACCESS Newswire December 16, 2024

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program

ACCESS Newswire December 5, 2024

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

ACCESS Newswire November 22, 2024

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis

ACCESS Newswire November 21, 2024

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results

ACCESS Newswire November 13, 2024

Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models

ACCESS Newswire November 12, 2024